## Jesus Castilla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5457082/publications.pdf

Version: 2024-02-01

213 papers 6,965 citations

39 h-index 98622 67 g-index

272 all docs

272 docs citations

times ranked

272

7819 citing authors

#	Article	IF	CITATIONS
1	Patient satisfaction with HIV care service in Spain: results from a cross-sectional patient survey. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 892-898.	0.6	4
2	Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. Emerging Infectious Diseases, 2022, 28, 137-138.	2.0	50
3	Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts. Postgraduate Medicine, 2022, 134, 230-238.	0.9	14
4	Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases. Scientific Reports, 2022, 12, 4862.	1.6	5
5	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Microbiology Spectrum, 2022, 10, e0000822.	1.2	17
6	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Eurosurveillance, 2022, 27, .	3.9	16
7	Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SplDnet observational multicentre study. Vaccine, 2022, 40, 3963-3974.	1.7	24
8	Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22. Eurosurveillance, 2022, 27, .	3.9	6
9	Independent Role of Severe Obesity as a Risk Factor for COVIDâ€19 Hospitalization: A Spanish Populationâ€Based Cohort Study. Obesity, 2021, 29, 29-37.	1.5	46
10	Self-Collection of Saliva Specimens as a Suitable Alternative to Nasopharyngeal Swabs for the Diagnosis of SARS-CoV-2 by RT-qPCR. Journal of Clinical Medicine, 2021, 10, 299.	1.0	12
11	Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Human Vaccines and Immunotherapeutics, 2021, 17, 1867-1872.	1.4	14
12	Absence of association between 2019â€20 influenza vaccination and COVIDâ€19: Results of the European Iâ€MOVEâ€COVIDâ€19 primary care project, Marchâ€August 2020. Influenza and Other Respiratory Viruses, 20.15, 429-438.	211.5	21
13	Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain. International Journal of Environmental Research and Public Health, 2021, 18, 2578.	1.2	5
14	Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19 Hospitalization and Severity: A Prospective Population-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 1194.	1.0	17
15	Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms, 2021, 9, 696.	1.6	10
16	Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer. Clinical Nutrition, 2021, 40, 1537-1545.	2.3	44
17	Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms, 2021, 9, 742.	1.6	30
18	Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance, 2021, 26, .	3.9	55

#	Article	IF	Citations
19	Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 2608.	1.0	42
20	Inflammatory Potential of the Diet and Incidence of Crohn's Disease and Ulcerative Colitis in the EPIC-Spain Cohort. Nutrients, 2021, 13, 2201.	1.7	5
21	Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Eurosurveillance, 2021, 26, .	3.9	38
22	Effect of influenza vaccination in patients with asthma. Cmaj, 2021, 193, E1120-E1128.	0.9	7
23	Simple models to include influenza vaccination history when evaluating the effect of influenza vaccination. Eurosurveillance, 2021, 26, .	3.9	4
24	Effectiveness of maternal pertussis vaccination in protecting newborn: A matched case-control study. Journal of Infection, 2021, 83, 554-558.	1.7	7
25	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance, 2021, 26, .	3.9	48
26	Dietary Constituents: Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up). International Journal of Environmental Research and Public Health, 2021, 18, 84.	1.2	4
27	Hepatitis A Outbreak Characteristics: A Comparison of Regions with Different Vaccination Strategies, Spain 2010–2018. Vaccines, 2021, 9, 1214.	2.1	3
28	Fatty acid intake and breast cancer in the Spanish multicase–control study on cancer (MCC-Spain). European Journal of Nutrition, 2020, 59, 1171-1179.	1.8	7
29	Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers. Vaccines, 2020, 8, 611.	2.1	29
30	Reply to: Comment to: Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factors. European Journal of Cancer Prevention, 2020, 29, 279-280.	0.6	0
31	Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population. Scientific Reports, 2020, 10, 8922.	1.6	39
32	Effect of Influenza Vaccination in Preventing Laboratory-Confirmed Influenza Hospitalization in Patients With Diabetes Mellitus. Clinical Infectious Diseases, 2020, 73, 107-114.	2.9	18
33	Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. GastroenterologAa Y HepatologAa (English Edition), 2020, 43, 248-255.	0.0	0
34	Vaccine effectiveness against influenza A(H3N2) and B among laboratoryâ€confirmed, hospitalised older adults, Europe, 2017â€18: A season of B lineage mismatched to the trivalent vaccine. Influenza and Other Respiratory Viruses, 2020, 14, 302-310.	1.5	15
35	Effectiveness of the current and prior influenza vaccinations in Northern Spain, 2018–2019. Vaccine, 2020, 38, 1925-1932.	1.7	9
36	Effect of antiviral treatment in older patients hospitalized with confirmed influenza. Antiviral Research, 2020, 178, 104785.	1.9	2

#	Article	IF	CITATIONS
37	Recapture of patients with an incomplete diagnosis of hepatitis C virus infection. Revista Espanola De Enfermedades Digestivas, 2020, 112, 525-531.	0.1	2
38	Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019. Revista Espanola De Enfermedades Digestivas, 2020, 113, 28-34.	0.1	4
39	Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. GastroenterologÃa Y HepatologÃa, 2020, 43, 248-255.	0.2	3
40	Association study of dietary non-enzymatic antioxidant capacity (NEAC) and colorectal cancer risk in the Spanish Multicase–Control Cancer (MCC-Spain) study. European Journal of Nutrition, 2019, 58, 2229-2242.	1.8	15
41	Natural Conception is Safe for HIV-Serodiscordant Couples with Persistent Suppressive Antiretroviral Therapy for the Infected Partner. Journal of Women's Health, 2019, 28, 1555-1562.	1.5	2
42	Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer. Scientific Reports, 2019, 9, 10847.	1.6	3
43	Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus. International Journal of Infectious Diseases, 2019, 89, 131-136.	1.5	13
44	Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Quality of Life Research, 2019, 28, 1477-1484.	1.5	17
45	Epstein Barr virus antibody reactivity and gastric cancer: A population-based case-control study. Cancer Epidemiology, 2019, 61, 79-88.	0.8	8
46	Remaining Effect of Influenza Vaccines Received in Prior Seasons. Journal of Infectious Diseases, 2019, 220, 1136-1140.	1.9	12
47	Flavonoids and the Risk of Gastric Cancer: An Exploratory Case-Control Study in the MCC-Spain Study. Nutrients, 2019, 11, 967.	1.7	22
48	Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factors. European Journal of Cancer Prevention, 2019, 28, 294-303.	0.6	15
49	Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax, 2019, 74, 473-482.	2.7	125
50	Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. Expert Review of Gastroenterology and Hepatology, 2019, 13, 699-708.	1.4	9
51	Low adherence to the western and high adherence to the mediterranean dietary patterns could prevent colorectal cancer. European Journal of Nutrition, 2019, 58, 1495-1505.	1.8	126
52	Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Revista Espanola De Enfermedades Digestivas, 2019, 111, 445-452.	0.1	27
53	La enfermedad por virus Zika en España. Resultados de la vigilancia y epidemiologÃa de los casos notificados en 2015-2017. Medicina ClÃnica, 2019, 153, 6-12.	0.3	4
54	Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. Postgraduate Medicine, 2018, 130, 317-324.	0.9	10

#	Article	lF	CITATIONS
55	Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly. European Journal of Public Health, 2018, 28, 150-155.	0.1	41
56	Meat intake, methods and degrees of cooking and breast cancer risk in the MCC-Spain study. Maturitas, 2018, 110, 62-70.	1.0	14
57	Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case–control study. Cmaj, 2018, 190, E3-E12.	0.9	40
58	A Composite of Functional Status and Pneumonia Severity Index Improves the Prediction of Pneumonia Mortality in Older Patients. Journal of General Internal Medicine, 2018, 33, 437-444.	1.3	21
59	Meat intake, cooking methods and doneness and risk of colorectal tumours in the Spanish multicase-control study (MCC-Spain). European Journal of Nutrition, 2018, 57, 643-653.	1.8	13
60	Estimación de la prevalencia de infección diagnosticada y no diagnosticada por el virus de la hepatitis C en Navarra, 2014-2016. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 325-331.	0.3	22
61	Asthma and influenza vaccination in elderly hospitalized patients: Matched case-control study in Spain. Journal of Asthma, 2018, 55, 391-401.	0.9	5
62	Pneumococcal Vaccination and Pneumonia Associated With Pleural Effusion in a Pediatric Population. Pediatric Infectious Disease Journal, 2018, 37, e87-e92.	1.1	9
63	Respiratory syncytial virus hospitalization in children in northern Spain. PLoS ONE, 2018, 13, e0206474.	1.1	26
64	Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS ONE, 2018, 13, e0208554.	1.1	16
65	Colorectal cancer, sun exposure and dietary vitamin D and calcium intake in the MCC-Spain study. Environment International, 2018, 121, 428-434.	4.8	23
66	Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE, 2018, 13, e0205277.	1.1	47
67	Detection of Respiratory Viruses in Deceased Persons, Spain, 2017. Emerging Infectious Diseases, 2018, 24, 1331-1334.	2.0	7
68	The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014–2016. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2018, 36, 325-331.	0.2	4
69	Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. Revista Espanola De Enfermedades Digestivas, 2018, 110, 621-628.	0.1	11
70	Comparison of influenza vaccine effectiveness in preventing outpatient and inpatient influenza cases in older adults, northern Spain, 2010/11 to 2015/16. Eurosurveillance, 2018, 23, .	3.9	16
71	Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. Eurosurveillance, 2018, 23, .	3.9	27
72	Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. Lancet Respiratory Medicine, the, 2017, 5, 200-211.	5.2	53

#	Article	IF	CITATIONS
73	Adherence to the Western, Prudent and Mediterranean dietary patterns and breast cancer risk: MCC-Spain study. Maturitas, 2017, 103, 8-15.	1.0	110
74	Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SplDnet countries: an observational multicentre study. Lancet Respiratory Medicine,the, 2017, 5, 648-656.	5.2	96
75	Adherence to nutritionâ€based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the <scp>MCC</scp> â€ <scp>S</scp> pain case–control study. International Journal of Cancer, 2017, 141, 83-93.	2.3	48
76	Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgraduate Medicine, 2017, 129, 476-483.	0.9	15
77	Assessment of clinical symptoms in household contacts of confirmed pertussis cases. Journal of Infection, 2017, 75, 426-432.	1.7	6
78	Helicobacter pylori serological biomarkers of gastric cancer risk in the MCC-Spain case-control Study. Cancer Epidemiology, 2017, 50, 76-84.	0.8	14
79	Antibody reactivity against <i>Helicobacter pylori</i> proteins in a sample of the Spanish adult population in 2008â€2013. Helicobacter, 2017, 22, e12401.	1.6	4
80	Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. Vaccine, 2017, 35, 4298-4306.	1.7	22
81	Source identification of autochthonous-introduced Plasmodium vivax Malaria, Spain. Infection, 2017, 45, 111-114.	2.3	8
82	Factors associated with acceptance of pandemic flu vaccine by healthcare professionals in Spain, 2009–2010. Research in Nursing and Health, 2017, 40, 435-443.	0.8	7
83	Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain. Frontiers in Microbiology, 2017, 8, 888.	1.5	20
84	Asthma in older people hospitalized with influenza in Spain: A case-control study. Allergy and Asthma Proceedings, 2017, 38, 277-285.	1.0	5
85	Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain. PLoS ONE, 2017, 12, e0171943.	1.1	16
86	Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus. Journal of Infectious Diseases, 2017, 215, 847-855.	1.9	35
87	Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain. PLoS ONE, 2017, 12, e0179160.	1.1	18
88	The effectiveness of influenza vaccination in preventing hospitalisations of elderly individuals in two influenza seasons: a multicentre case–control study, Spain, 2013/14 and 2014/15. Eurosurveillance, 2017, 22, .	3.9	10
89	Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. Eurosurveillance, 2017, 22, .	3.9	29
90	Combined effectiveness of prior and current season influenza vaccination in northern Spain: $2016/17$ mid-season analysis. Eurosurveillance, $2017$ , $22$ , .	3.9	24

#	Article	IF	CITATIONS
91	Factors influencing the spread of pertussis in households: a prospective study, Catalonia and Navarre, Spain, 2012 to 2013. Eurosurveillance, 2016, 21, .	3.9	17
92	Smoking may increase the risk of hospitalization due to influenza. European Journal of Public Health, 2016, 26, 882-887.	0.1	13
93	Effect of Occupational Exposure on A(H1N1)pdm09 Infection and Hospitalization. Annals of Occupational Hygiene, 2016, 60, 1009-1019.	1.9	3
94	Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy. Medicine (United States), 2016, 95, e4398.	0.4	22
95	Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Review of Vaccines, 2016, 15, 425-432.	2.0	41
96	High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case–Control Study. Archivos De Bronconeumologia, 2016, 52, 299-307.	0.4	14
97	Ãndice de masa corporal elevado como factor de riesgo de hospitalización por gripe: estudio de casos y controles. Archivos De Bronconeumologia, 2016, 52, 299-307.	0.4	16
98	Effectiveness of subunit influenza vaccination in the 2014–2015 season and residual effect of split vaccination in previous seasons. Vaccine, 2016, 34, 1350-1357.	1.7	32
99	Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study. Human Vaccines and Immunotherapeutics, 2016, 12, 1891-9.	1.4	24
100	Factors Associated with Influenza Vaccination of Hospitalized Elderly Patients in Spain. PLoS ONE, 2016, 11, e0147931.	1.1	19
101	Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study. Eurosurveillance, 2016, 21, .	3.9	26
102	Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season. Eurosurveillance, 2016, 21, .	3.9	20
103	Economic Evaluation of Health Services Costs During Pandemic Influenza A (H1N1) Pdm09 Infection in Pregnant and Non-Pregnant Women in Spain. Iranian Journal of Public Health, 2016, 45, 423-34.	0.3	4
104	Enhanced Estimates of the Influenza Vaccination Effect in Preventing Mortality. Medicine (United) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50
105	Comparison of body mass index (BMI) with the CUN-BAE body adiposity estimator in the prediction of hypertension and type 2 diabetes. BMC Public Health, 2015, 16, 82.	1.2	26
106	Managing an Online Survey about Influenza Vaccination in Primary Healthcare Workers. International Journal of Environmental Research and Public Health, 2015, 12, 541-553.	1.2	8
107	No Major Host Genetic Risk Factor Contributed to A(H1N1)2009 Influenza Severity. PLoS ONE, 2015, 10, e0135983.	1.1	22
108	Characteristics of Hospitalized Cases of Pertussis in Catalonia and Navarra, Two Regions in the North of Spain. PLoS ONE, 2015, 10, e0139993.	1.1	11

#	Article	IF	CITATIONS
109	Absence of transmission from HIV-infected individuals with HAART to their heterosexual serodiscordant partners. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 666-672.	0.3	7
110	Visualizing knowledge and attitude factors related to influenza vaccination of physicians. Vaccine, 2015, 33, 885-891.	1.7	14
111	Influenza vaccination of primary healthcare physicians may be associated with vaccination in their patients: a vaccination coverage study. BMC Family Practice, 2015, 16, 44.	2.9	32
112	Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. Human Vaccines and Immunotherapeutics, 2015, 11, 1626-1633.	1.4	20
113	Effectiveness of non-pharmaceutical measures in preventing pediatric influenza: a case–control study. BMC Public Health, 2015, 15, 543.	1.2	23
114	Pandemic Influenza A (H1N1) Infection in Pregnant and Nonpregnant Women in Spain (2009–2010). Japanese Journal of Infectious Diseases, 2014, 67, 163-171.	0.5	5
115	Household Transmission of Influenza A(H1N1)pdm09 in the Pandemic and Post-Pandemic Seasons. PLoS ONE, 2014, 9, e108485.	1.1	15
116	Knowledge of and attitudes to influenza in unvaccinated primary care physicians and nurses. Human Vaccines and Immunotherapeutics, 2014, 10, 2378-2386.	1.4	20
117	Pandemic Influenza A (H1N1) in Non-vaccinated, Pregnant Women in Spain (2009–2010). Maternal and Child Health Journal, 2014, 18, 1454-1461.	0.7	3
118	Predictors of advanced disease and late presentation in new HIV diagnoses reported to the surveillance system in Spain. Gaceta Sanitaria, 2014, 28, 116-122.	0.6	22
119	Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013. Vaccine, 2014, 32, 2553-2562.	1.7	69
120	Predictive factors of severe multilobar pneumonia and shock in patients with influenza. Emergency Medicine Journal, 2014, 31, 301-307.	0.4	3
121	Risk factors and effectiveness of preventive measures against influenza in the community. Influenza and Other Respiratory Viruses, 2013, 7, 177-183.	1.5	25
122	Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case–control study. BMC Public Health, 2013, 13, 191.	1.2	31
123	Social factors related to the clinical severity of influenza cases in Spain during the A (H1N1) 2009 virus pandemic. BMC Public Health, 2013, 13, 118.	1.2	20
124	Clinical features of influenza disease in admitted children during the first postpandemic season and risk factors for hospitalization: a multicentre Spanish experience. Clinical Microbiology and Infection, 2013, 19, E157-E162.	2.8	12
125	Estudio de actitudes y conocimientos sobre la vacunaci $ ilde{A}^3$ n antigripal en personal sanitario de atenci $ ilde{A}^3$ n primaria. Temporada 2011-2012. Vacunas, 2013, 14, 22-29.	1.1	3
126	Trends in influenza vaccine coverage among primary healthcare workers in Spain, 2008–2011. Preventive Medicine, 2013, 57, 206-211.	1.6	32

#	Article	IF	CITATIONS
127	Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. BMC Infectious Diseases, 2013, 13, 441.	1.3	46
128	Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed Influenza. Clinical Infectious Diseases, 2013, 57, 167-175.	2.9	112
129	Different prognosis in hospitalized patients with influenza one season after the pandemic <scp>H</scp> 1 <scp>N</scp> 1 influenza of 2009–2010 in <scp>S</scp> pain. Influenza and Other Respiratory Viruses, 2013, 7, 1336-1342.	1.5	6
130	Awareness and use of nonoccupational <scp>HIV</scp> postâ€exposure prophylaxis among people receiving rapid <scp>HIV</scp> testing in <scp>S</scp> pain. HIV Medicine, 2013, 14, 252-257.	1.0	24
131	Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons. Human Vaccines and Immunotherapeutics, 2013, 9, 865-873.	1.4	16
132	Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain. Human Vaccines and Immunotherapeutics, 2013, 9, 1172-1176.	1.4	32
133	Benefit of Conjugate Pneumococcal Vaccination in Preventing Influenza Hospitalization in Children. Pediatric Infectious Disease Journal, 2013, 32, 330-334.	1.1	15
134	2011â€"12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study. PLoS ONE, 2013, 8, e59681.	1.1	28
135	Knowledge of and Attitudes to Influenza Vaccination in Healthy Primary Healthcare Workers in Spain, 2011-2012. PLoS ONE, 2013, 8, e81200.	1.1	38
136	Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season $2011/12$ . Eurosurveillance, $2013$ , $18$ , .	3.9	132
137	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases, 2012, 54, 1364-1372.	2.9	58
138	Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. Journal of Antimicrobial Chemotherapy, 2012, 67, 1739-1745.	1.3	19
139	Factors associated with continued adherence to influenza vaccination in the elderly. Preventive Medicine, 2012, 55, 246-250.	1.6	33
140	SkutecznoÅ;ć szczepionek przeciw rotawirusom w zapobieganiu wystÄ™powania zachorowaÅ" i hospitalizacji z powodu rotawirusowego zapalenia ŽoÅ,Ä…dkowo-jelitowego w Nawarrze (Hiszpania). Pediatria Polska, 2012, 87, I-VI.	0.1	0
141	Score to identify the severity of adult patients with influenza A (H1N1) 2009 virus infection at hospital admission. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 2693-2701.	1.3	9
142	Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010–2011: Cohort and case–control study. Vaccine, 2012, 30, 195-200.	1.7	37
143	Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine, 2012, 30, 539-543.	1.7	69
144	Effectiveness of the 2010–11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine, 2012, 30, 3595-3602.	1.7	50

#	Article	IF	CITATIONS
145	Effectiveness of pandemic and seasonal influenza vaccines in preventing pandemic influenza-associated hospitalization. Vaccine, 2012, 30, 5644-5650.	1.7	10
146	Genetic diversity of influenza A(H1N1)2009 virus circulating during the season 2010–2011 in Spain. Journal of Clinical Virology, 2012, 53, 16-21.	1.6	18
147	Sociodemographic Factors and Clinical Conditions Associated to Hospitalization in Influenza A (H1N1) 2009 Virus Infected Patients in Spain, 2009–2010. PLoS ONE, 2012, 7, e33139.	1.1	20
148	2009 H1N1: risk factors for hospitalization in a matched case-control study. European Journal of Pediatrics, 2012, 171, 1127-1131.	1.3	13
149	Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization. Preventive Medicine, 2012, 54, 434-439.	1.6	52
150	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. Aids, 2012, 26, 1691-1705.	1.0	31
151	Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain. Journal of Clinical Virology, 2011, 51, 75-78.	1.6	30
152	Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain. Journal of Clinical Virology, 2011, 51, 205-208.	1.6	7
153	Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: Cohort and case-control study. Vaccine, 2011, 29, 5919-5924.	1.7	32
154	Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health, $2011,11,300.$	1.2	63
155	Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. BMC Public Health, 2011, 11, 899.	1.2	23
156	Use of Medical Care during Pandemic (H1N1) 2009, Navarre, Spain. Emerging Infectious Diseases, 2011, 17, 1463-6.	2.0	2
157	Educational level and HIV disease progression before and after the introduction of HAART: a cohort study in 989 HIV seroconverters in Spain. Sexually Transmitted Infections, 2011, 87, 571-576.	0.8	12
158	Auditing the Management of Vaccine-Preventable Disease Outbreaks: The Need for a Tool. PLoS ONE, 2011, 6, e15699.	1.1	3
159	Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: $2010/11$ mid-season analysis. Eurosurveillance, $2011$ , $16$ , .	3.9	10
160	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Aids, 2010, 24, 123-137.	1.0	360
161	Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ: British Medical Journal, 2010, 340, c2205-c2205.	2.4	147
162	Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network—Pilot case–control studies using different control groups, 2008–2009 season, Spain. Vaccine, 2010, 28, 2903-2907.	1.7	40

#	Article	IF	Citations
163	Mumps vaccine effectiveness in highly immunized populations. Vaccine, 2010, 28, 3567-3570.	1.7	27
164	Authors' reply: Estimating the impact of the 2009 influenza A(H1N1) pandemic on mortality in the elderly in Navarre, Spain. Eurosurveillance, 2010, $15$ , .	3.9	9
165	B:2a:P1.5 Meningococcal Strains Likely Arisen from Capsular Switching Event Still Spreading in Spain. Journal of Clinical Microbiology, 2009, 47, 463-465.	1.8	20
166	Human immunodeficiency virus testing uptake and risk behaviours in Spain. Journal of Epidemiology and Community Health, 2009, 63, 552-558.	2.0	18
167	Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART. Current HIV Research, 2009, 7, 612-619.	0.2	26
168	Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clinical Microbiology and Infection, 2009, 15, 1013-1019.	2.8	52
169	Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine, 2009, 27, 2089-2093.	1.7	29
170	Measles risk groups in Spain: Implications for the European measles-elimination target. Vaccine, 2009, 27, 3927-3934.	1.7	18
171	Reducing Sexual Risk Behavior Among Steady Heterosexual Serodiscordant Couples in a Testing and Counseling Program. Sexually Transmitted Diseases, 2009, 36, 621-628.	0.8	20
172	Population-based contact investigation of a cluster of tuberculosis cases in a small village. Epidemiology and Infection, 2009, 137, 1426-1435.	1.0	5
173	A large Legionnaires' disease outbreak in Pamplona, Spain: early detection, rapid control and no case fatality. Epidemiology and Infection, 2008, 136, 823-832.	1.0	33
174	Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine: A Population-Based Case-Control Study. Clinical Infectious Diseases, 2007, 44, 1436-1441.	2.9	66
175	Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. Journal of Medical Screening, 2007, 14, 14-20.	1.1	36
176	Vigilancia epidemiol $\tilde{A}^3$ gica de las enfermedades transmisibles en Navarra, 2006. Anales Del Sistema Sanitario De Navarra, 2007, 30, .	0.2	0
177	Delay in the Initiation of HAART, Poorer Virological Response, and Higher Mortality among HIV-Infected Injecting Drug Users in Spain. AIDS Research and Human Retroviruses, 2006, 22, 715-723.	0.5	63
178	Characteristics and trends of newly diagnosed HIV-infections, 2000-2004. Gaceta Sanitaria, 2006, 20, 442-448.	0.6	30
179	Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual Transmission of HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 96-101.	0.9	325
180	Impact of Chronic Hepatitis C on HIV-1 Disease Progression. HIV Clinical Trials, 2004, 5, 125-131.	2.0	44

#	Article	IF	CITATIONS
181	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. Journal of Viral Hepatitis, 2004, 11, 2-17.	1.0	65
182	Condiciones sociolaborales, conductas de riesgo y prevalencia de infecciones de transmisi $\tilde{A}^3$ n sexual en mujeres inmigrantes que ejercen la prostituci $\tilde{A}^3$ n en Madrid. Gaceta Sanitaria, 2004, 18, 177-183.	0.6	10
183	Condiciones sociolaborales, conductas de riesgo y prevalencia de infecciones de transmisi $\tilde{A}^3$ n sexual en mujeres inmigrantes que ejercen la prostituci $\tilde{A}^3$ n en Madrid. Gaceta Sanitaria, 2004, 18, 177-183.	0.6	45
184	Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sexually Transmitted Infections, 2003, 79, 160-162.	0.8	99
185	Incidence of Acquired Immunodeficiency Syndrome–Associated Opportunistic Diseases and the Effect of Treatment on a Cohort of 1115 Patients Infected with Human Immunodeficiency Virus, 1989–1997. Clinical Infectious Diseases, 2003, 36, 1177-1185.	2.9	90
186	Impact of Tuberculosis on HIV Disease Progression in Persons With Well-Documented Time of HIV Seroconversion. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 184-190.	0.9	28
187	Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sexually Transmitted Infections, 2002, 78, 255-260.	0.8	20
188	HIV infection among people of foreign origin voluntarily tested in Spain. A comparison with national subjects. Sexually Transmitted Infections, 2002, 78, 250-254.	0.8	26
189	Late diagnosis of HIV infection in the era of highly active antiretroviral therapy. Aids, 2002, 16, 1945-1951.	1.0	193
190	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. HIV Clinical Trials, 2002, 3, 99-114.	2.0	23
191	Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. Journal of Oral Pathology and Medicine, 2002, 31, 5-10.	1.4	62
192	Evaluating the risk of HIV transmission through unprotected orogenital sex. Aids, 2002, 16, 1296-1297.	1.0	52
193	Oferta generalizada de la prueba del virus de la inmunodeficiencia humana a embarazadas: todavÃa lejos de los niveles deseables. Medicina ClÃnica, 2001, 116, 518-519.	0.3	0
194	CD4 lymphocyte percentage vs CD4 lymphocyte count as an immunological marker of oral candidiasis in HIV-infected patients. Oral Diseases, 2001, 7, 203-204.	1.5	0
195	Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. Journal of Medical Virology, 2001, 64, 217-222.	2.5	10
196	The completeness of AIDS surveillance in Europe: difficulties and new challenges. Journal of Epidemiology and Community Health, 2001, 55, 7-8.	2.0	6
197	Sociodemographic characteristics and HIV risk behaviour patterns of male sex workers in Madrid, Spain. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2001, 13, 677-682.	0.6	53
198	Time trend in incidence of HIV seroconversion among homosexual men repeatedly tested in Madrid, 1988–2000. Aids, 2001, 15, 1319-1321.	1.0	37

#	Article	IF	CITATIONS
199	Seroprevalence of HIV and HTLV in a representative sample of the Spanish population. Epidemiology and Infection, 2000, 125, 159-162.	1.0	15
200	Drug and alcohol consumption and sexual risk behaviour among young adults: results from a national survey. Drug and Alcohol Dependence, 1999, 56, 47-53.	1.6	87
201	Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. Aids, 1999, 13, 525.	1.0	25
202	Low seroincidence and decrease in seroprevalence of HIV among female prostitutes in Madrid. Aids, 1999, 13, 1143.	1.0	11
203	The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. Journal of Infection, 1998, 36, 307-311.	1.7	20
204	Lack of benefit or protease inhibitors on HCV viremia in HIV- infected patients. Journal of Hepatology, 1998, 28, 526-527.	1.8	52
205	Sexual behaviour and condom use in the general population of Spain, 1996. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1998, 10, 667-676.	0.6	28
206	Pulmonary and extrapulmonary tuberculosis at AIDS diagnosis in Spain. Aids, 1997, 11, 1583-1588.	1.0	25
207	Viral load in relation to clinical outcome in HIV-infected children. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 900-900.	1.3	1
208	Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients. European Journal of Epidemiology, 1996, 12, 91-92.	2.5	26
209	Interferon  for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1996, 23, 585-591.	2.9	187
210	Sociodemographic predictors and temporal trends of extrapulmonary tuberculosis as an AIDS-defining disease in Spain. Aids, 1995, 9, 383-388.	1.0	5
211	The AIDS Epidemic among Spanish Women. International Journal of Epidemiology, 1995, 24, 619-624.	0.9	5
212	A temporal-spatial cluster of sudden infant death syndrome in Navarre, Spain. European Journal of Epidemiology, 1994, 10, 129-134.	2.5	2
213	Marked impact of the expanded AIDS case definition in Spain. Aids, 1994, 8, 1632.	1.0	4